Device Trial Radar · NCT05881655
Slow Myopia Progression With Different Irradiance Light
Last checked: Nov 20, 2026Latest source record: May 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
75
Planned (sponsor's estimate)
Start
May 20, 2023
Primary completion
May 30, 2024
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Beijing Airdoc Technology Co., Ltd.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Shanghai Children's Medical Center
- First posted
- May 31, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 6 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is a prospective clinical control study on red light control myopia with specail design spectacles for 75 children in 3 groups. Study Groups with two different powers of 0.6 mW and 1.2 mW at wavelength of 650nm. The control group is to wear the same brand and design spectalces as those two study groups. In addition, the progression of myopia is usually accompanied by the changes in a variety of ocular parameters, such as refractive error, reduced submacular choroidal thickness, and prolonged length of the ocular axis length.The goal is to test which power (1.2mW and 0.6mW) is better in myopic children for 3 month's follow-up and also to test how to get better result with the increaing or decreasing lighting power for the total 6 month follow-up results .
Conditions
- Myopia, Progressive
Interventions
Airdoc Red Lighting DeviceDevice
A medical device with ultra low lever laser irradiance of 0.6mW or 1.2mW at the surface of cornea. And the therapy lasts 3 minutes with the 4 hours or more interval of break.
Special Spectacles to Control MyopiaDevice
Customer designed power and fitting to each subject for all the study periods.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change of Ocular Axial length elongation at follow-up from Baseline (mm)Time frame: 3-month
- Mean Change of Ocular Axial length elongation at follow-up from Baseline (mm)Time frame: 6-month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Children Medical Center
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.